Want to see GB:GENI full AI Analyst Report?
GENinCode UK Ltd. (GENI) Share Price & Analysis
GENI Stock Chart & Stats
- Day’s Range
- GBX 0.50 - GBX 0.62
- 52-Week Range
- GBX 0.50 - GBX 4.90
- Previous Close
- GBX 0.55
- Volume
- N/A
- Average Volume (3M)
- 2.65M
- Market Cap
- GBP 4.89M
- Enterprise Value
- GBP 4.24M
- Total Cash (Recent Filing)
- GBP 2.05M
- Total Debt (Recent Filing)
- GBP 98.00K
- Price to Earnings (P/E)
- ―
- Beta
- -0.46
- Next Earnings
- Jun 08, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue Growth
The acceleration in revenue growth indicates improving commercial traction and broader adoption of the company’s diagnostic offering. If sustained, stronger top-line expansion can improve operating leverage, support investment in the business, and help the company progress toward a more viable scale.
Improving Gross Margin
Higher gross margin suggests that the company is retaining more revenue after direct costs, strengthening the underlying economics of each sale. Continued margin improvement could provide a foundation for reducing operating losses as revenue expands, although current profitability remains weak.
Modest Absolute Debt
A small absolute debt burden limits the immediate scale of fixed repayment obligations and leaves some financial flexibility compared with a heavily debt-funded business. This provides a relative balance-sheet advantage, although continuing losses and reduced equity still constrain that flexibility.
Bears Say
Deep And Persistent Unprofitability
The depth and persistence of losses show that current revenue remains far below the level needed to cover the company’s cost base. Without a material improvement in operating efficiency or scale, ongoing losses can consume capital, restrict investment capacity, and delay a credible path to profitability.
Continued Cash Burn
Persistent negative operating and free cash flow indicates that the business is not yet self-funding and must continue absorbing cash to operate. Sustained cash burn can increase reliance on external financing, limit strategic choices, and make progress toward cash breakeven more difficult.
Equity Erosion And Rising Leverage
The sharp erosion of equity materially reduces the cushion available to absorb further losses and has made the debt burden larger relative to the capital base. If losses continue, financial flexibility may weaken further, increasing balance-sheet risk despite the small absolute debt level.
GENinCode UK Ltd. News
GENI FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
What is GENinCode UK Ltd.’s market cap?
When is GENinCode UK Ltd.’s upcoming earnings report date?
How were GENinCode UK Ltd.’s earnings last quarter?
Is GENinCode UK Ltd. overvalued?
Does GENinCode UK Ltd. pay dividends?
What is GENinCode UK Ltd.’s EPS estimate?
How many shares outstanding does GENinCode UK Ltd. have?
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Matthew Heaton Walls
- Employees
- 44
- Website
- www.genincode.com
- Address
- One St. Peters Square, Manchester, GM, M2 3DE, GB
GENinCode UK Ltd. (GENI) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |










